Publicaciones en colaboración con investigadores/as de Centro de Investigación Biomédica en Red sobre Enfermedades Raras (34)

2021

  1. Micrornas targeting HIF-2α, VEGFR1 and/or VEGFR2 as potential predictive biomarkers for VEGFR tyrosine kinase and HIF-2α inhibitors in metastatic clear-cell renal cell carcinoma

    Cancers, Vol. 13, Núm. 12

2019

  1. Concomitant Medications and Risk of Chemotherapy-Induced Peripheral Neuropathy

    Oncologist, Vol. 24, Núm. 8, pp. e784-e792

  2. Deep sequencing reveals microRNAs predictive of antiangiogenic drug response

    JCI Insight, Vol. 1, Núm. 10

  3. Integrative multi-omics analysis identifies a prognostic miRNA signature and a targetable miR-21-3p/TSC2/ mTOR axis in metastatic pheochromocytoma/ paraganglioma

    Theranostics, Vol. 9, Núm. 17, pp. 4946-4958

2018

  1. Gain-of-function mutations in DNMT3A in patients with paraganglioma

    Genetics in Medicine, Vol. 20, Núm. 12, pp. 1644-1651

2017

  1. Genetic variation in the NEIL2 DNA glycosylase gene is associated with oxidative DNA damage in BRCA2 mutation carriers

    Oncotarget, Vol. 8, Núm. 70, pp. 114626-114636

  2. Multilayer OMIC Data in medullary thyroid carcinoma identifies the STAT3 pathway as a potential therapeutic target in RETM918T Tumors

    Clinical Cancer Research, Vol. 23, Núm. 5, pp. 1334-1345

  3. Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer

    PLoS ONE, Vol. 12, Núm. 7

  4. Targeted sequencing reveals low-frequency variants in EPHA genes as markers of paclitaxel-induced peripheral neuropathy

    Clinical Cancer Research, Vol. 23, Núm. 5, pp. 1227-1235

2016

  1. Molecular insights into the OGG1 gene, a cancer risk modifier in BRCA1 and BRCA2 mutations carriers

    Oncotarget, Vol. 7, Núm. 18, pp. 25815-25825

2015

  1. DNA methylation profiling in pheochromocytoma and paraganglioma reveals diagnostic and prognostic markers

    Clinical Cancer Research, Vol. 21, Núm. 13, pp. 3020-3030

  2. Functional and in silico assessment of MAX variants of unknown significance

    Journal of Molecular Medicine, Vol. 93, Núm. 11, pp. 1247-1255

  3. High frequency and founder effect of the CYP3A4∗20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme

    Pharmacogenomics Journal, Vol. 15, Núm. 3, pp. 288-292

  4. MicroRNA deep-sequencing reveals master regulators of follicular and papillary thyroid tumors

    Modern Pathology, Vol. 28, Núm. 6, pp. 748-757

  5. Recommendations for somatic and germline genetic testing of single pheochromocytoma and paraganglioma based on findings from a series of 329 patients

    Journal of Medical Genetics, Vol. 52, Núm. 10, pp. 647-656

  6. Thyroid cancer GWAS identifies 10q26.12 and 6q14.1 as novel susceptibility loci and reveals genetic heterogeneity among populations

    International Journal of Cancer, Vol. 137, Núm. 8, pp. 1870-1878

  7. Whole-exome sequencing identifies MDH2 as a new familial paraganglioma gene

    Journal of the National Cancer Institute, Vol. 107, Núm. 5

2014

  1. DNA methylation profiling of well-differentiated thyroid cancer uncovers markers of recurrence free survival

    International Journal of Cancer, Vol. 135, Núm. 3, pp. 598-610

2013

  1. An Epistatic Interaction between the PAX8 and STK17B Genes in Papillary Thyroid Cancer Susceptibility

    PLoS ONE, Vol. 8, Núm. 9

  2. Differential gene expression of medullary thyroid carcinoma reveals specific markers associated with genetic conditions

    American Journal of Pathology, Vol. 182, Núm. 2, pp. 350-362